Lilly, PTC snap up bankrupt Sangamo's main assets
Just a few weeks after filing for bankruptcy protection, Sangamo has found buyers for some of its key assets, raising up to $85 million.
Sangamo Therapeutics
Sangamo Therapeutics (NASDAQ: SGMO) is a genomic medicine company headquartered in Richmond, California, focused on translating ground-breaking science into genomic medicines using zinc finger nucleases (ZFNs), zinc finger protein transcription factors (ZFP-TFs), and adeno-associated virus (AAV) delivery. Sangamo's clinical-stage pipeline includes giroctocogene fitelparvovec (hemophilia A gene therapy, partnered with Pfizer) and isavufermin or SAR445136 (alpha-1 antitrypsin deficiency, partnered with Sanofi). The company is also developing preclinical in vivo genome-editing programs and ex vivo gene-edited cell therapies.
Company Info
Sector:Genomic Medicine / Gene Therapy
Headquarters:Richmond, California, USA
Founded:1995
Website:www.sangamo.com/
Recent News
Sangamo's three-decade run comes to a close as Lilly and Astellas eye assets
Sangamo Therapeutics filed for bankruptcy after three decades in genomic medicine, with Eli Lilly and Astellas emerging as stalking horse bidders for its Fabry gene therapy and other key assets.
Leadership Team
Alexander (Sandy) Macrae
Chief Executive Officer and President